Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Liss

Showing results (221-230 of 256) with videos related to

Pageof 26
Sort By:
The American Journal of Managed Care|January 17, 2018
Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assayJulie A Lynch, Megan P Rothney, Raoul R Salup, et al.
Magnetic Resonance Imaging|July 30, 2015
Prostate diffusion imaging with distortion correctionRebecca A Rakow-Penner, Nathan S White, Daniel J A Margolis, et al.
Clinical and Translational Radiation Oncology|May 28, 2026
Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancerAnna M Dornisch, Mariluz Rojo Domingo, Roberta Vezza Alexander, et al.
Cancers|May 13, 2026
C-Reactive Protein/Albumin Ratio (CAR)-Integrated IMDC Model Improves Risk Stratification in Metastatic Renal Cell CarcinomaAaron I Ahdoot, Cesare Saitta, Giuseppe Garofano, et al.
The Journal of Urology|April 9, 2025
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA TrialAlon Lazarovich, Hari Vigneswaran, Thorgerdur Palsdottir, et al.
The Journal of Urology|July 8, 2025
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: ErratumAlon Lazarovich, Hari Vigneswaran, Thorgerdur Palsdottir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered TrialHari T Vigneswaran, Martin Eklund, Andrea Discacciati, et al.
Prostate Cancer and Prostatic Diseases|January 13, 2016
In vivo prostate cancer detection and grading using restriction spectrum imaging-MRIK C McCammack, C J Kane, J K Parsons, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2015
Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extensionR A Rakow-Penner, N S White, J K Parsons, et al.
Pageof 26

Showing results (221-230 of 256) with videos related to

Sort By:
Pageof 26
The American Journal of Managed Care|January 17, 2018
Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assayJulie A Lynch, Megan P Rothney, Raoul R Salup, et al.
Magnetic Resonance Imaging|July 30, 2015
Prostate diffusion imaging with distortion correctionRebecca A Rakow-Penner, Nathan S White, Daniel J A Margolis, et al.
Clinical and Translational Radiation Oncology|May 28, 2026
Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancerAnna M Dornisch, Mariluz Rojo Domingo, Roberta Vezza Alexander, et al.
Cancers|May 13, 2026
C-Reactive Protein/Albumin Ratio (CAR)-Integrated IMDC Model Improves Risk Stratification in Metastatic Renal Cell CarcinomaAaron I Ahdoot, Cesare Saitta, Giuseppe Garofano, et al.
The Journal of Urology|April 9, 2025
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA TrialAlon Lazarovich, Hari Vigneswaran, Thorgerdur Palsdottir, et al.
The Journal of Urology|July 8, 2025
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: ErratumAlon Lazarovich, Hari Vigneswaran, Thorgerdur Palsdottir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered TrialHari T Vigneswaran, Martin Eklund, Andrea Discacciati, et al.
Prostate Cancer and Prostatic Diseases|January 13, 2016
In vivo prostate cancer detection and grading using restriction spectrum imaging-MRIK C McCammack, C J Kane, J K Parsons, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2015
Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extensionR A Rakow-Penner, N S White, J K Parsons, et al.
Pageof 26